Radovan Vojtíšek1, Emília Sukovská2, Jan Baxa3, Marie Budíková4, Petra Kovářová2, Jindřich Fínek2. 1. Department of Oncology and Radiotherapy, University Hospital in Pilsen, alej Svobody 80, 304 60, Pilsen, Czech Republic. vojtisekr@fnplzen.cz. 2. Department of Oncology and Radiotherapy, University Hospital in Pilsen, alej Svobody 80, 304 60, Pilsen, Czech Republic. 3. Department of Imaging Methods, University Hospital in Pilsen, alej Svobody 80, 304 60, Pilsen, Czech Republic. 4. Department of Mathematics and Statistics, Faculty of Science, Masaryk University in Brno, Kotlářská 2, 611 37, Brno, Czech Republic.
Abstract
PURPOSE: This article reports experiences with 3T magnetic resonance imaging(MRI)-guided brachytherapy (BT) for cervical cancer focusing on late side effects. METHODS: Between June 2012 and March 2017 a total of 257 uterovaginal BT administrations were performed in 61 consecutive patients with inoperable cervical cancer. All patients were treated with BT combined with external beam radiotherapy. RESULTS: The mean HR-CTV (high risk-clinical target volume) D90 was 87 ± 5.1 Gy equivalent dose corresponding to the conventional fractionation using 2 Gy per fraction (EQD2, range 70.7-97.9 Gy). The mean doses in OAR (organs at risk), namely rectum, sigmoid and bladder were D2 cm3rectum = 62.6 ± 6.9 Gy EQD2 (range 38.2-77.2 Gy), D2 cm3sigmoid = 66.2 ± 6.8 Gy EQD2 (43.2-78.6 Gy) and D2 cm3bladder = 75.1 ± 8.3 Gy EQD2 (58.2-92.6 Gy). There were no signs of late gastrointestinal (GI) toxicity in 49 patients, grade 3 toxicity was seen in 2 patients and grade 4 toxicity in 3 patients. There were no signs of late genitourinary (GU) toxicity in 41 patients, grade 3 toxicity was seen in 4 patients and no signs of grade 4 toxicity were seen. After the treatment, 60 patients (98.4%) achieved locoregional remission. In 54 patients (88.5%) the remission was complete, whereas in 6 patients (9.8%) remission was partial. CONCLUSION: The use of 3T MRI-guided BT leads to achievement of high rates of local control with limited late morbidity as demonstrated in this series of patients.
PURPOSE: This article reports experiences with 3T magnetic resonance imaging(MRI)-guided brachytherapy (BT) for cervical cancer focusing on late side effects. METHODS: Between June 2012 and March 2017 a total of 257 uterovaginal BT administrations were performed in 61 consecutive patients with inoperable cervical cancer. All patients were treated with BT combined with external beam radiotherapy. RESULTS: The mean HR-CTV (high risk-clinical target volume) D90 was 87 ± 5.1 Gy equivalent dose corresponding to the conventional fractionation using 2 Gy per fraction (EQD2, range 70.7-97.9 Gy). The mean doses in OAR (organs at risk), namely rectum, sigmoid and bladder were D2 cm3rectum = 62.6 ± 6.9 Gy EQD2 (range 38.2-77.2 Gy), D2 cm3sigmoid = 66.2 ± 6.8 Gy EQD2 (43.2-78.6 Gy) and D2 cm3bladder = 75.1 ± 8.3 Gy EQD2 (58.2-92.6 Gy). There were no signs of late gastrointestinal (GI) toxicity in 49 patients, grade 3 toxicity was seen in 2 patients and grade 4 toxicity in 3 patients. There were no signs of late genitourinary (GU) toxicity in 41 patients, grade 3 toxicity was seen in 4 patients and no signs of grade 4 toxicity were seen. After the treatment, 60 patients (98.4%) achieved locoregional remission. In 54 patients (88.5%) the remission was complete, whereas in 6 patients (9.8%) remission was partial. CONCLUSION: The use of 3T MRI-guided BT leads to achievement of high rates of local control with limited late morbidity as demonstrated in this series of patients.
Entities:
Keywords:
3D brachytherapy; 3T MRI-guided brachytherapy; Cervical cancer; Late side effects; Uterovaginal brachytherapy
Authors: Richard Pötter; Christine Haie-Meder; Erik Van Limbergen; Isabelle Barillot; Marisol De Brabandere; Johannes Dimopoulos; Isabelle Dumas; Beth Erickson; Stefan Lang; An Nulens; Peter Petrow; Jason Rownd; Christian Kirisits Journal: Radiother Oncol Date: 2006-01-05 Impact factor: 6.280
Authors: Akila N Viswanathan; Sushil Beriwal; Jennifer F De Los Santos; D Jeffrey Demanes; David Gaffney; Jorgen Hansen; Ellen Jones; Christian Kirisits; Bruce Thomadsen; Beth Erickson Journal: Brachytherapy Date: 2012 Jan-Feb Impact factor: 2.362
Authors: Beant S Gill; Hayeon Kim; Christopher J Houser; Joseph L Kelley; Paniti Sukumvanich; Robert P Edwards; John T Comerci; Alexander B Olawaiye; Marilyn Huang; Madeleine Courtney-Brooks; Sushil Beriwal Journal: Int J Radiat Oncol Biol Phys Date: 2015-01-30 Impact factor: 7.038
Authors: Johannes C A Dimopoulos; Stefan Lang; Christian Kirisits; Elena F Fidarova; Daniel Berger; Petra Georg; Wolfgang Dörr; Richard Pötter Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-14 Impact factor: 7.038
Authors: Richard Pötter; Johannes Dimopoulos; Petra Georg; Stefan Lang; Claudia Waldhäusl; Natascha Wachter-Gerstner; Hajo Weitmann; Alexander Reinthaller; Tomas Hendrik Knocke; Stefan Wachter; Christian Kirisits Journal: Radiother Oncol Date: 2007-05 Impact factor: 6.280
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Radovan Vojtíšek; Petr Hošek; Emília Sukovská; Petra Kovářová; Jan Baxa; Jiří Ferda; Jindřich Fínek Journal: Strahlenther Onkol Date: 2022-01-21 Impact factor: 4.033
Authors: Stéphanie Smet; Nicole Nesvacil; Johannes Knoth; Alina Sturdza; Dina Najjari-Jamal; Filip Jelinek; Gernot Kronreif; Richard Pötter; Joachim Widder; Christian Kirisits; Maximilian P Schmid Journal: Strahlenther Onkol Date: 2020-07-03 Impact factor: 3.621